Coherent Corp. (COHR) › Analysis

Coherent (COHR) stock analysis, November 3, 2026: Downtrend intact after 39% drop, earnings due tomorrow

Published November 3, 2026 · updated 2026-11-11 · COHR chart, levels and live analysis

Update, November 11, 2026

Coherent (COHR) jumped 11.3% on the day and is up 22.4% over the past five trading sessions, outpacing the S&P 500’s modest 0.8% gain and the technology‑focused XLK’s 2.7% rise, while volume remains 56% below its 20‑day average.

The picture holds: COHR is still trading below the 247.02 swing‑zone resistance and the daily close remains above the downside breakout trigger of 230.15. The stop at 252.42 and the two target levels of 204.06 and 200.18 are unchanged, as is the weekly close‑above rule at 255.19 that would alter the outlook. The stock’s 50‑day SMA sits at 267.01, reinforcing the downtrend, and the RSI is near 51, indicating no immediate overbought pressure.

Recent earnings showed a 50% YoY revenue jump and a GAAP EPS of $1.90, but the rally has been short‑lived, with the price now 23.9% below the 40‑week average. What would change the picture? A weekly close above 255.19 would reset the bias. Sources: Wall Street Journal and Seeking Alpha.

Coherent Corp. (COHR) trades at $206.33 on November 3, 2026 after a 3.19% bounce on the day, but the stock is still 39% below its October 6 peak of $338.36 and under both its 50-day and 200-day averages. Over the next two to six weeks the balance of evidence leans negative, with high conviction. Earnings arrive tomorrow, and nothing in the news explains the latest leg down.

Why it matters

There is no single event behind this move. It is a run-up on AI optics enthusiasm followed by a sharp reversal. On October 22, 2026 the shares fell 11.3% to $210.81 after Susquehanna cut its price target from $425 to $350 while keeping a Positive rating, as Investing.com reported. A rebound followed. The stock rose 7.4% on October 26 when StoneX started coverage with a Buy and a $425 target. It reached $241.80 on October 29 on reports that Marvell was in advanced talks to buy Lumentum. Today the price is back near the October 22 low, so every rally since the peak has been sold.

That pattern says the good news was already in the price. At $338.36 the stock was discounting years of capacity growth, so even a price target that stayed positive was enough to trigger an 11% drop. The one-month change is -38.95%, against -2.05% for the S&P 500 (SPY). The stock is still up 11.48% for the year, which shows how much of the gain has been given back in a few weeks.

The last five days are the clearest case. COHR fell 12.74%, while SPY lost 2.06% and the technology sector ETF (XLK) lost 7.07%. The market explains a small slice. The sector explains more: on October 22, Investing.com showed Marvell down 9.29% and AMD down 7.83%. The stock itself accounts for the remaining 5.7 points of underperformance against XLK. No article in the feed explains that extra weakness, so it should be treated as selling pressure without a named cause.

The argument about COHR is real on both sides. The positive case is that Evercore ISI expects FCC restrictions on foreign-produced optical transceivers by the first quarter of 2027, which would remove Chinese suppliers from the U.S. market for 3.2T transceivers. StoneX points to six-inch indium phosphide capacity that management plans to double successively through the end of 2027. The cautious side rests on price. Susquehanna's cut to $350 shows that even supporters trimmed their numbers, and the stock has lagged the S&P 500 by 24.0% over 50 days.

Valuation shows how far apart price and opinion have drifted. Twenty-five analysts rate the stock a buy, with a mean target of $387.80 and a range of $230 to $500. The price is 46.8% below that mean and below even the lowest target. Either the targets are stale or the market is pricing a risk the analysts have not yet written down. At a market value of about $40.6 billion, the stock is being treated as damaged rather than merely cheap.

What the evidence says

On the long term, the thesis is weakened and the stock is in a downtrend phase. Price is below its 40-week average, the 50-day average at $276.40 sits under the 200-day at $296.61, and the shares are 51.67% below the 52-week high of $426.89. It is not a broken story: the price is still 60.31% above the 52-week low of $128.70. But the phase is a markdown after a sharp peak, and those tend to be uneven rather than quick.

For the next two to six weeks the balance of evidence leans negative, with high conviction: three of four checks line up. The daily trend runs with the weekly downtrend. The stock trails SPY by 24.0% over 50 days and trails XLK by 19.5%. Today's bounce came on volume 45% below the 20-day average, which is thin support for a recovery.

The strongest case against this reading is the oversold condition. The 14-day RSI is 30.31, today's gain was 3.19%, and earnings tomorrow can move the stock sharply either way. It does not tip the balance, because oversold readings often persist in downtrends and the last bounce, to $241.80, ended well under the $255.19 level that would matter. Earnings risk is the reason the reading is not stronger.

Levels that matter

In a downtrend the structure holds below $225.00, a round number where sellers have shown up on rallies. $230.15 sits just above it, then $250.00. The trend would end above $255.19, a swing zone that would need a weekly close, not a single day's spike. The 50-day average at $276.40 is the next reference. Below the price, support is $204.06, then $200.18, then $175.00, with the 52-week low of $128.70 as the outer marker.

The downside breakout level is a daily close below $204.06. From there the first target is $200.18, only 0.2 to 1 against a stop at $229.69, which is $225.00 plus a quarter of the 14-day average true range. The second target, the 52-week low at $128.70, gives 2.9 to 1. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would need a trigger lower than $204.06 or a tighter stop than $229.69, and the near target never gets close either way.

What would change the picture

A weekly close above $255.19 would be the first sign that buyers have regained control and that the downtrend is over. The non-price fact most likely to produce it is an earnings report that confirms the indium phosphide capacity ramp is on schedule and that demand supports it. That would give the positive case in the debate its first hard evidence since the peak.

What to watch

Get a message when the COHR picture changes — the agent team watches the levels and the news for you.Create a free account

More COHR analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.